



GLB/WDN:gte 9/14/04 2004-01-01 306161.doc
4FPO-05-15

DT07 Rec'd PCT/PTO 17 SEP 2004

PCT

PATENT
Attorney Reference Number 7037-69151-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kim et al.

Application No. 10/500,696

Filed: July 1, 2004

Confirmation No. Not yet assigned

For: NOVEL ANTI-VIRAL VSF PROTEIN
AND HYBRIDOMA PRODUCING THE
SAME

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 7037-69151-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed September 14, 2004

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Supplemental Information Disclosure Statement
- ☒ Form 1449 and a copy of the reference cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By
Gillian L. Bunker, Ph.D.
Registration No. 47,461

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446
cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Kim et al.

Application No. 10/500,696

Filed: July 1, 2004

Confirmation No. Not yet assigned

For: NOVEL ANTI-VIRAL VSF PROTEIN AND
HYBRIDOMA PRODUCING THE SAME

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 7037-69151-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent

for Applicant(s)

Date Mailed September 14, 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal sheet for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Gillian L. Bunker, Ph.D.

Registration No. 47,461

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Attorney Docket Number	7037-69151-01
Application Number	10/500,696
Filing Date	July 1, 2004
First Named Inventor	Kim
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

**Examiner's
Initials*****Cite No.
(optional)****OTHER DOCUMENTS**

FROLOV *et al.*, "Quantification of Endogenous Viral Polymerase, 3D^{pol}, in Preparations of Mengo and Encephalomyocarditis Viruses," *Virology* 260(1):148-155, 1999, abstract only

**EXAMINER
SIGNATURE:****DATE
CONSIDERED:**

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.